Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
Abstract: Selective targeting of the functionally exhausted malignant T cells in cutaneous T-cell lymphoma (CTCL) and distinct cells within the tumor microenvironment (TME) via programmed cell death 1/programmed cell death ligand 1 blockade (durvalumab) may restore an antitumor immune response. The...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2025-05-01
|
| Seri Bilgileri: | Blood Advances |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2473952925001065 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|